Nyrada Inc (ASX: NYR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Nyrada Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.73 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 179.41 million
Earnings per share -0.032
Dividend per share N/A
Year To Date Return 350.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Nyrada Inc (ASX: NYR)
    Latest News

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    Guess which ASX pharmaceuticals stock is up 400% in 2 days

    Big returns have been generated from this pharma stock this week.

    Read more »

    NYR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Nyrada Inc

    Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

    NYR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 Apr 2024 $0.11 $0.01 10.10% 1,743,388 $0.10 $0.12 $0.10
    11 Apr 2024 $0.10 $-0.01 -9.52% 4,036,660 $0.11 $0.11 $0.10
    10 Apr 2024 $0.11 $-0.03 -23.08% 6,033,902 $0.13 $0.13 $0.10
    09 Apr 2024 $0.13 $-0.01 -7.41% 3,134,028 $0.14 $0.14 $0.12
    08 Apr 2024 $0.14 $0.02 16.67% 6,041,091 $0.12 $0.15 $0.11
    05 Apr 2024 $0.12 $0.02 20.41% 4,951,532 $0.10 $0.13 $0.10
    04 Apr 2024 $0.10 $0.01 10.99% 511,538 $0.09 $0.10 $0.09
    03 Apr 2024 $0.09 $0.00 0.00% 446,675 $0.09 $0.10 $0.09
    02 Apr 2024 $0.09 $-0.01 -10.10% 997,020 $0.10 $0.10 $0.09
    28 Mar 2024 $0.10 $0.01 11.11% 4,324,435 $0.09 $0.10 $0.09
    27 Mar 2024 $0.09 $-0.01 -10.42% 906,671 $0.10 $0.10 $0.09
    26 Mar 2024 $0.10 $0.00 0.00% 2,080,984 $0.11 $0.11 $0.10
    25 Mar 2024 $0.10 $0.00 0.00% 853,798 $0.11 $0.11 $0.10
    22 Mar 2024 $0.11 $-0.01 -9.09% 833,133 $0.11 $0.11 $0.10
    21 Mar 2024 $0.11 $0.01 10.00% 902,267 $0.11 $0.12 $0.10
    20 Mar 2024 $0.10 $0.00 0.00% 1,008,829 $0.11 $0.11 $0.10
    19 Mar 2024 $0.11 $-0.01 -8.70% 4,099,835 $0.12 $0.12 $0.11
    18 Mar 2024 $0.12 $0.00 0.00% 6,572,712 $0.11 $0.13 $0.11
    15 Mar 2024 $0.12 $0.02 20.00% 5,778,369 $0.10 $0.12 $0.10
    14 Mar 2024 $0.10 $-0.03 -23.08% 4,562,256 $0.13 $0.13 $0.10
    13 Mar 2024 $0.13 $-0.02 -13.33% 15,206,690 $0.14 $0.17 $0.13

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Mar 2024 John Moore Expiry 1,200,000 $120,000
    Options expired.
    14 Mar 2024 Christopher Cox Expiry 600,000 $60,000
    Options expired.
    14 Mar 2024 Marcus Frampton Expiry 600,000 $60,000
    Options expired.
    14 Mar 2024 Ruediger Weseloh Expiry 600,000 $60,000
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Ian Edward Dixon FounderNon-Executive Director Sep 2020
    Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd. He is member of Risk committee.
    Mr John Alexander Moore Non-Executive ChairmanNon-Executive Director Jun 2019
    Mr Moore currently serves as Chairman of Trialogics, a clinical trial informatics business, Chairman of Scientific Industries (SCND-OTCQB), a producer of laboratory instruments for the life sciences industry and Chairman of Cormetech, a manufacturer of environmental catalysts. John was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix business was acquired for US$11 million and sold for US$101 million, and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals. He is a member of Risk Committee.
    Mr Ruediger Weseloh Non-Executive Director Jun 2019
    Mr Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 17 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, Ruediger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck Institute for Experimental Medicine in Goettingen.
    Mr Christopher Cox Non-Executive Director Nov 2019
    Mr Cox is a Co-Founder and has been a Managing Partner of Population Health Partners since April 2020. Chris is a retired Partner of Cadwalader, Wickersham & Taft LLP a position he held from January 2012. He remains a Senior Attorney of the firm. Previously the Chairman of Cadwalader's Corporate Department and a member of its Management Committee, Chris advised clients on a wide array of corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetisation's and other complex financing transactions. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Before January 2012, Chris was a partner at Cahill Gordon & Reindel LLP in New York. Chris also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in biotechnology, network security and entertainment
    Mr Marcus Frampton Non-Executive Director Jun 2019
    Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$77 billion sovereign wealth fund for the State of Alaska. Marcus manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, Marcus held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). In addition to his duties at the APFC, Marcus is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a leading manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems.He is a member of Risk Committee.
    Dr Gisela Mautner Non-Executive Director Aug 2022
    Ms Mautner is an international business leader with experience in developing and launching new pharmaceutical products and delivering corporate strategies in highly competitive global markets. Gisela has held senior positions with Amgen, Bayer, Siemens Medical Solutions and Merck/MSD generating commercial and scientific outcomes. She is currently the Past-President of the Medical Affairs Professionals Association of Australasia (MAPA) and a Member of the Australian Institute of Company Directors and the CEO Institute. She is also a Non-executive Director of a not-for-profit organisation
    Mr David James Franks Company Secretary
    -
    Mr James Bonnar Chief Executive Officer
    -
    James Bonnar Chief Executive Officer
    -
    David James Franks Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Noxopharm Limited 33,373,245 21.39%
    Altnia Holding Pty Ltd<I Dixon Family A/C> 9,921,725 6.36%
    Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 2,400,000 1.54%
    Kyriaco Barber Pty Ltd 1,982,498 1.27%
    Colin Housely & Freda Housely <Cm Housley & Fv Housley Fam> 1,863,725 1.19%
    Superhero Securities Limited <Client A/C> 1,793,715 1.15%
    Himstedt & Co Pty Ltd <The Himstedt Family A/C> 1,760,500 1.13%
    Mr Nicholas John Axam 1,731,400 1.11%
    Symphony Capital Holdings Llc 1,425,000 0.91%
    Professor Gary David Housley 1,411,411 0.90%
    Mr John Gardner 1,400,000 0.90%
    Harlund Investments Pty Ltd <Hart Family Super Fund A/C> 1,400,000 0.90%
    Dossman Pty Ltd 1,353,705 0.87%
    Mr Anthony John Locantro 1,327,567 0.85%
    John W King Nominees Pty Ltd 1,242,483 0.80%
    Rhlc Pty Limited <Rhlc S/F A/C> 1,210,000 0.78%
    Mr Colin James Easterbrook & Mrs Janet Elizabeth Easterbrook <C & J Easterbrook Super A/C> 1,200,000 0.77%
    Canary Capital Pty Ltd 1,134,615 0.73%
    Dixson Trust Pty Limited 1,100,000 0.71%
    Mr Graham Arthur Robinson 1,082,888 0.69%

    Profile

    since

    Note